Pre-exposure Prophylaxis: The Delivery Challenge

Pre-exposure Prophylaxis (PrEP)

In 2012, the US Food and Drug Administration (FDA) approved Truvada to be used as PrEP by HIV negative people who are at high risk of sexually acquired HIV infection. The US Centre for Disease Control has since developed guidelines and recommended PrEP be used by people at high risk of HIV acquisition via sexual transmission or injection drug use (http://www.cdc.gov/hiv/prevention/research/prep/).

Annotated Bibliography: Pre-Exposure Prophylaxis

Pre-exposure rabies prophylaxis: a systematic review

OBJECTIVE To review the safety and immunogenicity of pre-exposure rabies prophylaxis (including accelerated schedules, co-administration with other vaccines and booster doses), its cost-effectiveness and recommendations for use, particularly in high-risk settings. METHODS We searched the PubMed, Centre for Agriculture and Biosciences International, Cochrane Library and Web of Science database...

Pre-Exposure Prophylaxis YouTube Videos: Content Evaluation

BACKGROUND Antiretroviral (ARV) medicines reduce the risk of transmitting the HIV virus and are recommended as daily pre-exposure prophylaxis (PrEP) in combination with safer sex practices for HIV-negative individuals at a high risk for infection, but are underused in HIV prevention. Previous literature suggests that YouTube is extensively used to share health information. While pre-exposure pr...

A community perspective on pre-exposure prophylaxis

The history of pre-exposure prophylaxis (PrEP) is notable for being a community rather than industry-driven development. This talk will review this history, covering factors that include community demand, study results, regulatory challenges, commercial interests and practical issues of public health. It will also look at some of the controversies that appear to limit broader access, and import...